# How the 2026 compounding policy treats single ingredients

- Article ID: research-053
- Product: BPC-157 / TB-500 (bpc-157-tb-500-576)
- Canonical page: https://heritagebiolabs.com/research-library/articles/053-how-the-2026-compounding-policy-treats-single-ingredients
- Product collection: https://heritagebiolabs.com/research-library/products/bpc-157-tb-500
- Product page: https://heritagebiolabs.com/product/bpc-157-tb-500-576
- Reading focus: Mechanisms & biology (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short amino-acid chains joined by peptide bonds. Their sequences let researchers distinguish one active substance from another, even when both are studied for similar effects. BPC-157 is a synthetic 15-amino-acid peptide, and TB-500 is defined in an October 2026 U.S. policy as an acetylated seven-amino-acid fragment related to thymosin beta-4. The policy gives each substance its own identity and addresses a specific question about compounding under federal law. [1] [2]

The U.S. Department of Health and Human Services published a notice announcing its interim enforcement discretion policy for certain bulk peptide substances under section 503A. The policy identifies BPC-157 acetate and TB-500 acetate individually. It sets conditions concerning the identity and quality of the bulk material and the reporting of adverse events. One condition specifies that a compounded product contains a single active ingredient from the policy's list. HHS explains that single-ingredient products make it easier to associate an observed outcome or adverse event with a specific substance. [1] [2]

A mixture containing both BPC-157 and TB-500 would have two active ingredients and falls outside that single-ingredient condition. Naming both substances in the same policy does not supply evidence that they are effective together. The notice addresses the circumstances under which HHS says it does not intend to take enforcement action while the bulk substances list is developed through rulemaking. That is distinct from FDA approval of a finished product for an indication. [1] [2]

For a reader evaluating a claim about the combination, the scope of the policy and the scope of the clinical evidence are separate. The former can be read directly in the published conditions. The latter depends on studies that identify and test the two ingredients together. [1] [2]

## Sources

1. U.S. Department of Health and Human Services. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Federal Register (publication 2026-10-30). <https://www.govinfo.gov/content/pkg/FR-2026-10-30/pdf/2026-22192.pdf>
2. U.S. Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. U.S. Department of Health and Human Services (publication 2026-10). <https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 011 - BPC-157 TB-500 and Cagrilintide.docx; article 53; content SHA-256 ea1f4f8458b327fc97f907145218c6be862be80b57738b12546ba743930ad05b.
